The Efficiency and Safety of PRP Treatment After Anterior Cruciate Ligament Reconstruction.
Launched by NICOLAUS COPERNICUS UNIVERSITY IN TORUŃ, COLLEGIUM MEDICUM IN BYDGOSZCZ · May 29, 2024
Trial Information
Current as of February 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of platelet-rich plasma (PRP) treatment after surgery to repair the anterior cruciate ligament (ACL) in the knee. The ACL is crucial for stabilizing the knee, and injuries to it are common, especially among younger athletes. After ACL reconstruction surgery, many patients develop early arthritis, which can lead to long-term joint problems. Researchers want to see if injecting PRP, which contains concentrated platelets that can help reduce inflammation and promote healing, can improve recovery and prevent cartilage damage after surgery.
To participate in this trial, you must be between 18 and 45 years old and have undergone ACL reconstruction. You should have a healthy weight and no significant previous knee injuries or other health issues that could affect your participation. If you join the study, you will receive PRP injections and will need to avoid other knee treatments and certain pain medications for the duration of the trial. The goal is to find out if this treatment can help improve knee function and reduce the risk of arthritis after ACL surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subject is 18-45 years old
- • subject has BMI \< 40 kg/m2
- • subject had ACL reconstrution
- • small asymptomatic meniscal lesions that won't require repair
- • subject must be willing to abstain from other intra-articular treatments of the knee for the duration of the study.
- • subject is willing to discontinue all analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs), except tramadol and paracetamol, at least one month before the synovial fluid aspiration and through the completion of the study
- • subject is able to understand and comply with the requirements of the study and voluntarily provides consent
- Exclusion Criteria:
- • subject has a history of metabolic diseases, endocrine disorders, rheumatic and connective tissue diseases, cancer, hormonal contraception, steroid therapy, antibiotic therapy
- • subject had an intraarticular injection into the affected joint
- • subject had previous operations (beside ACL reconstruction) or fractures of the affected limb
- • subject has a history of nicotine, alcohol, or drug addiction
- • subject has a meniscal tear that requires suturing or total meniscectomy seen on MRI
- • subject has multi-ligament knee injuries or multi-organ injury
- • subject has significant varus or valgus deformity greater than 10 degrees in either knee, determined by an X-ray
About Nicolaus Copernicus University In Toruń, Collegium Medicum In Bydgoszcz
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, is a leading academic institution dedicated to advancing medical research and education. Renowned for its commitment to excellence, the university fosters a collaborative environment that integrates clinical practice with innovative research. Through rigorous clinical trials, it aims to contribute significantly to the fields of medicine and healthcare, focusing on improving patient outcomes and enhancing scientific knowledge. With a team of experienced researchers and access to state-of-the-art facilities, the institution is well-positioned to explore cutting-edge therapeutic interventions and address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toruń, , Poland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0